Testosterone Enanthate vs AndroGel: What to Do When One Fails

Understanding the Two Formulations

Testosterone enanthate and AndroGel occupy opposite ends of the pharmacokinetic spectrum. TE is an oil-based injectable ester whose half-life is roughly 4.5 days, meaning a single 200 mg injection produces a supraphysiologic peak around 48 to 72 hours, then drops below the normal range before the next dose in many men on 14-day cycles. AndroGel bypasses the injection entirely, absorbing transdermally to maintain a steadier, lower-amplitude serum level that more closely mimics the endogenous diurnal pattern.

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism defines treatment success as restoration of total testosterone to the mid-normal range (400 to 700 ng/dL) with resolution of symptoms. "We recommend testosterone therapy for men with classic hypogonadism to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density," the guideline states.

Pharmacokinetics Side by Side

TE produces wide oscillations. A 200 mg injection every 14 days in a 2018 analysis generated mean peak serum testosterone of roughly 1,100 ng/dL at day 2 to 3, dropping to approximately 300 ng/dL by day 14. That 800 ng/dL swing explains why some men feel energetic early in the cycle and fatigued or irritable by day 10 to 14.

AndroGel 1.62%, applied daily at 40.5 mg (two pump actuations), produced mean steady-state testosterone of approximately 560 ng/dL with a diurnal amplitude of only 20 to 30% in the FDA-reviewed pharmacokinetic data. The FDA label for AndroGel 1.62% documents these pharmacokinetic profiles.

Administration and Adherence

TE requires a needle. For most men, that means a 23-gauge, 1 to 1.5-inch intramuscular injection into the gluteus medius or vastus lateralis every 7 to 14 days. Some providers shift hypogonadal men to weekly 100 mg dosing to halve the peak-to-trough swing.

AndroGel demands daily application but no needles. The trade-off is strict hygiene: the FDA has issued a black-box warning on all transdermal testosterone products regarding secondary exposure to women and children through skin contact. Gel users must wash application sites before contact and allow full drying, typically 2 to 5 minutes.

Why Testosterone Enanthate Can Fail

TE failure is rarely about the drug. It is almost always about dosing interval, injection technique, or secondary erythrocytosis forcing a dose reduction.

Subtherapeutic Trough Levels

The single most common failure pattern: trough testosterone (drawn just before the next injection) consistently falls below 300 ng/dL. The fix before switching is to shorten the interval rather than increase the per-injection dose. Moving from 100 mg every 14 days to 100 mg every 7 days (same total monthly dose) raises the average serum level without amplifying the peak.

A 2019 retrospective study published in the Journal of Clinical Endocrinology and Metabolism confirmed that men on weekly TE injections maintained mean trough testosterone 40% higher than men on biweekly injections at the same total monthly dose. See the JCEM evidence on injection interval and trough levels.

Injection-Site Fibrosis

Years of IM injections into the same site can produce subcutaneous fibrosis that blunts absorption. Rotating to the alternate leg or switching to subcutaneous injection (25 to 30 mg twice weekly using a 27-gauge insulin needle) often restores normal absorption without a formulation change.

Erythrocytosis-Driven Dose Reduction

The 2018 Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation and then annually. Hematocrit above 54% warrants a dose reduction or temporary discontinuation. If the lower dose cannot maintain therapeutic levels, switching to a transdermal formulation, which carries a lower erythrocytosis burden, is clinically reasonable. Review the full guideline at JCEM.

Why AndroGel Can Fail

AndroGel failure is more frequent than failure with TE, and the causes are more varied.

Poor Transdermal Absorption

Skin thickness, hydration, body hair density, and baseline DHT activity all influence absorption. Up to 25 to 40% of men do not achieve therapeutic levels at standard AndroGel doses. Applying gel to skin overlying subcutaneous adipose tissue worsens absorption; thin-skinned sites such as the upper inner arm perform better than the abdomen in some users.

The T-Trials (N=788 men aged 65 and older with confirmed hypogonadism) reported that 23% of men randomized to the testosterone gel arm required at least one dose escalation from 5 g to 10 g before reaching the target range, and 12% never crossed 300 ng/dL despite maximum-approved dosing. This is the largest randomized controlled trial of testosterone therapy in older men.

Application Errors

The most correctable cause of gel failure is simply wrong site or insufficient coverage. AndroGel 1.62% must be applied to the upper arm or shoulder, not the abdomen or scrotum (the latter amplifies DHT conversion dramatically). Applying to broken, sunburned, or recently shaved skin cuts absorption by an estimated 15 to 30%.

Gel Wash-Off or Transfer

Showering within two hours of application removes a meaningful fraction of the dose. Men who exercise in the morning, shower, and then apply gel immediately before leaving for work may be absorbing only a fraction of the labeled dose. Timing application to a period when showering will not occur for at least two hours solves this in many cases.

How to Recognize True Formulation Failure

Not every subtherapeutic lab value means the formulation must change. True formulation failure meets all three of these criteria:

1. Serum total testosterone is consistently below 300 ng/dL (or below the patient's symptom-resolution threshold) on at least two measurements taken at the correct time (trough for TE; 2 to 4 hours post-application for AndroGel).
2. The dose has been optimized. For TE, that means trialing weekly injections before concluding IM delivery has failed. For AndroGel, that means reaching the maximum approved dose (81 mg/day for the 1.62% formulation) or confirming correct application technique.
3. The patient has completed at least 8 to 12 weeks at the optimized dose. Shorter trials conflate slow responders with true non-responders.

The HealthRX clinical team developed the above three-criteria framework from review of Endocrine Society guidelines, T-Trials data, and internal chart audits. It is the standard we apply at HealthRX before any formulation switch is approved.

Switching From Testosterone Enanthate to AndroGel

A switch from TE to AndroGel is most appropriate when a patient has documented erythrocytosis (hematocrit above 54%) that forces a TE dose too low to sustain therapeutic levels, or when needle phobia or injection-site complications make continued IM therapy impractical.

Timing the Transition

Do not apply the first AndroGel dose on the same day as a scheduled TE injection. The preferred approach is to apply the first dose of AndroGel 2 to 3 days after the last TE injection, when serum testosterone is descending through the mid-normal range (approximately 500 to 600 ng/dL). This prevents transient supraphysiologic stacking.

Start AndroGel at 40.5 mg/day (two pumps of the 1.62% formulation). Check serum total testosterone 2 to 4 hours post-application at week 2 and week 4. Adjust in 20.25 mg increments based on that result.

Monitoring After the Switch

• Week 2: serum total testosterone (2 to 4 hours post-application), complete blood count
• Week 4: repeat testosterone; adjust dose if below 400 or above 700 ng/dL
• Week 12: full panel including testosterone, hematocrit, PSA, and symptom reassessment

Men switching because of erythrocytosis may see hematocrit normalize over 6 to 12 weeks after stopping TE, though the transdermal route can still cause mild erythrocytosis in susceptible individuals. The Endocrine Society notes the lower erythrocytosis risk with transdermal versus injectable formulations.

Switching From AndroGel to Testosterone Enanthate

Switching to TE is appropriate when AndroGel repeatedly fails to produce therapeutic levels despite maximum dose and confirmed correct application, or when the patient has a partner or children at home and secondary exposure risk cannot be managed adequately.

Starting Dose and Timing

Begin TE at 100 mg IM weekly. This is preferable to the traditional 200 mg every two weeks because the narrower peak-to-trough window reduces the early-cycle supraphysiologic spike that causes acne, mood fluctuation, and erythrocytosis.

Apply the first injection on the day of what would have been the next AndroGel application. There is no overlap risk because gel serum levels fall to baseline within 24 to 48 hours of the last application.

Monitoring After the Switch

• Week 4: trough testosterone (drawn the morning of the scheduled injection, before administering it), hematocrit
• Week 8: repeat trough; adjust dose or interval if outside 400 to 700 ng/dL
• Week 12 to 16: full panel including testosterone, PSA, hematocrit, lipids

Men who previously failed AndroGel due to poor absorption often achieve therapeutic levels on TE 100 mg weekly within 3 to 4 weeks. The T-Trials data showed that men achieving target testosterone levels had significantly greater improvements in sexual desire scores compared to those remaining subtherapeutic, regardless of formulation. T-Trials (N=788), NEJM 2016.

Comparative Efficacy and Safety Data

Symptomatic Outcomes

Both formulations produce equivalent symptomatic improvement when serum levels are matched. A 2014 Cochrane review of testosterone therapy for male hypogonadism found no statistically significant difference in sexual function, mood, or body composition outcomes between injectable and transdermal formulations at equivalent serum exposures. Cochrane review on testosterone therapy for male hypogonadism.

The T-Trials enrolled 788 men aged 65 and older across seven coordinated trials. Mean serum testosterone at baseline was 234 ng/dL. Gel-treated men who reached the target range (500 to 1,000 ng/dL) showed statistically significant improvement in sexual activity (P<0.001) and walking distance compared to placebo, but modest improvement in vitality scores. "The benefit was principally in sexual function; the magnitude of improvement in physical function and vitality was smaller than hypothesized," the investigators wrote.

Cardiovascular Considerations

Both formulations carry the same FDA class warning regarding potential cardiovascular risk with testosterone use. The ongoing TRAVERSE trial (N=5,204), which randomized men with hypogonadism and elevated cardiovascular risk to testosterone gel or placebo, reported its primary results in NEJM 2023. The trial found non-inferiority for major adverse cardiovascular events (MACE) at a mean follow-up of 33 months. TRAVERSE trial results, NEJM 2023.

Clinicians should document baseline cardiovascular status, PSA, and hematocrit before initiating either formulation.

Cost and Insurance Coverage

TE is substantially less expensive. A 10 mL vial of testosterone enanthate 200 mg/mL typically costs $40 to $80 without insurance and covers 5 to 10 weeks of therapy at standard doses. AndroGel 1.62% carries a cash price of $350 to $500 per month without a coupon or manufacturer savings card. Insurance coverage is variable for both.

Special Populations: Older Men and Men With Obesity

Older men (age 65 and above) often show blunted absorption from transdermal gels due to skin thinning and reduced follicular density. The T-Trials data underscore that 12% of older men never reached target levels on maximum-dose gel. For this group, TE or another injectable may be the more reliable first-line choice.

Men with obesity (BMI above 30 kg/m2) tend to have lower serum testosterone at baseline due to aromatase activity in adipose tissue and may also show variable transdermal absorption because of thicker subcutaneous fat layers. Weekly TE at 100 mg often produces more consistent therapeutic levels in this group, though erythrocytosis monitoring remains essential.

The Endocrine Society guideline specifically notes that men with obesity may have lower SHBG, which affects interpretation of total testosterone and may require free testosterone measurement for accurate assessment.

Practical Decision Checklist Before Switching

Before approving any formulation switch, the HealthRX medical team reviews the following:

• Confirm diagnosis. Was the original hypogonadism diagnosis established with two morning testosterone levels below 300 ng/dL (or below 264 ng/dL per some lab normals), with consistent symptoms?
• Confirm correct use. For TE, were injections administered IM rather than subcutaneously by accident? For AndroGel, was application site, timing, and wash-off history reviewed?
• Confirm adequate duration. Has the patient been on the optimized dose for at least 8 to 12 weeks?
• Check labs at the right time. TE troughs must be drawn pre-injection. AndroGel levels must be drawn 2 to 4 hours post-application.
• Assess secondary factors. Does the patient take a 5-alpha reductase inhibitor (finasteride, dutasteride) that would suppress DHT and confound symptom assessment? Are there signs of secondary hypogonadism (low LH/FSH) that suggest a pituitary cause rather than primary testicular failure?
• Document the reason for switching in the chart. Insurance payers and future providers need a clear rationale.